Innovative Technology Remedium Bio’s proprietary Prometheus™ platform enables safe, effective, and adjustable gene therapy delivery, which positions it as a pioneering solution for healthcare providers seeking advanced and customizable treatments in regenerative medicine.

Expanding Pipeline With pipeline development in Weight Loss, Type 2 Diabetes, and Stroke, Remedium Bio offers multiple opportunities for clinical partnership, licensing, and distribution agreements across diverse therapeutic areas that address high unmet clinical needs.

Strategic Collaborations Recent collaborations with Lilly and academic institutions highlight potential for joint development, licensing, and funding opportunities that can accelerate product commercialization and expand market reach.

Funding Growth Having secured initial seed funding of over $2.3 million and demonstrating revenue in the range of up to $10 million, Remedium Bio presents an attractive opportunity for investors and partners interested in early-stage, high-impact biotech ventures.

Market Positioning Targeting large unmet needs with innovative gene therapies, especially for conditions like Osteoarthritis and Diabetes, positions Remedium Bio as a promising partner for healthcare organizations and payers looking for durable, cost-effective treatments.